507 related articles for article (PubMed ID: 20581313)
21. KIR B haplotype donors confer a reduced risk for relapse after haploidentical transplantation in children with ALL.
Oevermann L; Michaelis SU; Mezger M; Lang P; Toporski J; Bertaina A; Zecca M; Moretta L; Locatelli F; Handgretinger R
Blood; 2014 Oct; 124(17):2744-7. PubMed ID: 25115891
[TBL] [Abstract][Full Text] [Related]
22. Increased donor inhibitory KIR are associated with reduced GVHD and improved survival following HLA-matched unrelated donor HCT in paediatric acute leukaemia.
Krieger E; Qayyum R; Toor A
Br J Haematol; 2024 May; 204(5):1935-1943. PubMed ID: 38442905
[TBL] [Abstract][Full Text] [Related]
23. Presence of donor-encoded centromeric KIR B content increases the risk of infectious mortality in recipients of myeloablative, T-cell deplete, HLA-matched HCT to treat AML.
Bultitude WP; Schellekens J; Szydlo RM; Anthias C; Cooley SA; Miller JS; Weisdorf DJ; Shaw BE; Roberts CH; Garcia-Sepulveda CA; Lee J; Pearce RM; Wilson MC; Potter MN; Byrne JL; Russell NH; MacKinnon S; Bloor AJ; Patel A; McQuaker IG; Malladi R; Tholouli E; Orchard K; Potter VT; Madrigal JA; Mayor NP; Marsh SGE
Bone Marrow Transplant; 2020 Oct; 55(10):1975-1984. PubMed ID: 32203258
[TBL] [Abstract][Full Text] [Related]
24. A Phase 2 Trial of KIR-Mismatched Unrelated Donor Transplantation Using in Vivo T Cell Depletion with Antithymocyte Globulin in Acute Myelogenous Leukemia: Children's Oncology Group AAML05P1 Study.
Davies SM; Iannone R; Alonzo TA; Wang YC; Gerbing R; Soni S; Kolb EA; Meshinchi S; Orchard PJ; Burns LJ; Shenoy S; Leung W
Biol Blood Marrow Transplant; 2020 Apr; 26(4):712-717. PubMed ID: 31870931
[TBL] [Abstract][Full Text] [Related]
25. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
26. KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation.
Weisdorf D; Cooley S; Wang T; Trachtenberg E; Vierra-Green C; Spellman S; Sees JA; Spahn A; Vogel J; Fehniger TA; Woolfrey AE; Devine SM; Ross M; Waller EK; Sobecks RM; McGuirk J; Oran B; Farag SS; Shore T; Van Besien K; Marsh SGE; Guethlein LA; Parham P; Miller JS
Blood Adv; 2020 Feb; 4(4):740-754. PubMed ID: 32092137
[TBL] [Abstract][Full Text] [Related]
27. Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide.
Shimoni A; Labopin M; Lorentino F; Van Lint MT; Koc Y; Gülbas Z; Tischer J; Bruno B; Blaise D; Pioltelli P; Afanasyev B; Ciceri F; Mohty M; Nagler A
Leukemia; 2019 Jan; 33(1):230-239. PubMed ID: 29907809
[TBL] [Abstract][Full Text] [Related]
28. Donor selection for KIR B haplotype of the centromeric motifs can improve the outcome after HLA-identical sibling hematopoietic stem cell transplantation.
Zhou H; Bao X; Wu X; Tang X; Wang M; Wu D; He J
Biol Blood Marrow Transplant; 2013 Oct; ():. PubMed ID: 24513672
[TBL] [Abstract][Full Text] [Related]
29. Donor KIR Genotype Impacts on Clinical Outcome after T Cell-Depleted HLA Matched Related Allogeneic Transplantation for High-Risk Pediatric Leukemia Patients.
Escudero A; Martínez-Romera I; Fernández L; Valentín J; González-Vicent M; Vicario JL; Madero-Jarabo R; Diaz MÁ; Pérez-Martínez A
Biol Blood Marrow Transplant; 2018 Dec; 24(12):2493-2500. PubMed ID: 30145228
[TBL] [Abstract][Full Text] [Related]
30. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy.
Hsu KC; Gooley T; Malkki M; Pinto-Agnello C; Dupont B; Bignon JD; Bornhäuser M; Christiansen F; Gratwohl A; Morishima Y; Oudshoorn M; Ringden O; van Rood JJ; Petersdorf E;
Biol Blood Marrow Transplant; 2006 Aug; 12(8):828-36. PubMed ID: 16864053
[TBL] [Abstract][Full Text] [Related]
31. Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cells.
Verheyden S; Ferrone S; Mulder A; Claas FH; Schots R; De Moerloose B; Benoit Y; Demanet C
Cancer Immunol Immunother; 2009 Jun; 58(6):855-65. PubMed ID: 18841361
[TBL] [Abstract][Full Text] [Related]
32. Systematic evaluation of donor-KIR/recipient-HLA interactions in HLA-matched hematopoietic cell transplantation for AML.
Fein JA; Shouval R; Krieger E; Spellman SR; Wang T; Baldauf H; Fleischhauer K; Kröger N; Horowitz M; Maiers M; Miller JS; Mohty M; Nagler A; Weisdorf D; Malmberg KJ; Toor AA; Schetelig J; Romee R; Koreth J
Blood Adv; 2024 Feb; 8(3):581-590. PubMed ID: 38052043
[TBL] [Abstract][Full Text] [Related]
33. The impact of donor full-length KIR2DS4 in the development of acute and chronic GVHD after unrelated allogeneic HSCT.
An K; Li B; Luo C; Wang J; Luo C; Chen J
Pediatr Transplant; 2020 Sep; 24(6):e13728. PubMed ID: 32594584
[TBL] [Abstract][Full Text] [Related]
34. Mesenchymal stem cells enhance the impact of KIR receptor-ligand mismatching on acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia but not in those with acute lymphocytic leukemia.
Zhang Y; Zheng H; Ren J; Luo X; Zheng Z; Zheng J; Zheng X; Chen Y; Chen Z; Hu J; Yang T
Hematol Oncol; 2021 Aug; 39(3):380-389. PubMed ID: 33848027
[TBL] [Abstract][Full Text] [Related]
35. [Genes of killer cell immunoglobulin-like receptors and their HLA ligands after allogeneic hematopoietic stem cell transplantation in myeloid leukemia patients].
Khamaganova EG; Parovichnikova EN; Kuzmina LA; Kulikov SM; Savchenko VG
Ter Arkh; 2015; 87(11):68-77. PubMed ID: 26821420
[TBL] [Abstract][Full Text] [Related]
36. Killer Cell Immunoglobulin-Like Receptor-Ligand Matching and Outcomes after Unrelated Cord Blood Transplantation in Acute Myeloid Leukemia.
Rocha V; Ruggeri A; Spellman S; Wang T; Sobecks R; Locatelli F; Askar M; Michel G; Arcese W; Iori AP; Purtill D; Danby R; Sanz GF; Gluckman E; Eapen M;
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1284-1289. PubMed ID: 27090957
[TBL] [Abstract][Full Text] [Related]
37. Prospective KIR genotype evaluation of hematopoietic cell donors is feasible with potential to benefit patients with AML.
Shaffer BC; Le Luduec JB; Park S; Devlin S; Archer A; Davis E; Cooper C; Nhaissi M; Suri B; Wells D; Tamari R; Papadopoulos E; Jakubowski AA; Giralt S; Hsu KC
Blood Adv; 2021 Apr; 5(7):2003-2011. PubMed ID: 33843984
[TBL] [Abstract][Full Text] [Related]
38. KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia.
Willemze R; Rodrigues CA; Labopin M; Sanz G; Michel G; Socié G; Rio B; Sirvent A; Renaud M; Madero L; Mohty M; Ferra C; Garnier F; Loiseau P; Garcia J; Lecchi L; Kögler G; Beguin Y; Navarrete C; Devos T; Ionescu I; Boudjedir K; Herr AL; Gluckman E; Rocha V;
Leukemia; 2009 Mar; 23(3):492-500. PubMed ID: 19151783
[TBL] [Abstract][Full Text] [Related]
39. Following Transplantation for Acute Myelogenous Leukemia, Donor
Guethlein LA; Beyzaie N; Nemat-Gorgani N; Wang T; Ramesh V; Marin WM; Hollenbach JA; Schetelig J; Spellman SR; Marsh SGE; Cooley S; Weisdorf DJ; Norman PJ; Miller JS; Parham P
J Immunol; 2021 Jun; 206(12):3064-3072. PubMed ID: 34117109
[TBL] [Abstract][Full Text] [Related]
40. External validation of models for KIR2DS1/KIR3DL1-informed selection of hematopoietic cell donors fails.
Schetelig J; Baldauf H; Heidenreich F; Massalski C; Frank S; Sauter J; Stelljes M; Ayuk FA; Bethge WA; Bug G; Klein S; Wendler S; Lange V; de Wreede LC; Fürst D; Kobbe G; Ottinger HD; Beelen DW; Mytilineos J; Fleischhauer K; Schmidt AH; Bornhäuser M
Blood; 2020 Apr; 135(16):1386-1395. PubMed ID: 31932846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
